Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Financial Select Sector SPDR Fund — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Financial Select Sector SPDR Fund trades at $54.63 (market cap $52.24B). The key difference: Financial Select Sector SPDR Fund is far larger — about 10.7× Travere Therapeutics Inc. Common Stock's market cap, and Financial Select Sector SPDR Fund is more actively traded (44,490,388 versus 1,668,577). Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Financial Select Sector SPDR Fund for 104 Days on average.
| TVTX | XLF | |
|---|---|---|
Market Cap | $4.88B | $52.24B |
Volume | 1,668,577 | 44,490,388 |
Sector | Health | — |
52-Week High | $67.52 | $58.55 |
52-Week Low | $26.79 | $47.80 |
Typical Hold Time | 0 Days | 104 Days |
Enterprise Value | $5.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
XLF trades at $54.82, down 0.42% amid mixed technical signals with a bullish moving average trend but neutral oscillators. The ETF faces sector headwinds as financial stocks lag the broader market despite rising bank profits. Recent Federal Reserve stress test changes and interest rate hikes create both opportunities and challenges for financial sector performance.
The financial sector ETF shows potential for benefiting from rising interest rates, though regulatory uncertainty and market underperformance relative to the S&P 500 present near-term risks. Institutional rotation into financials in Q2 2026 suggests confidence in the sector's rate sensitivity advantages over technology stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
